NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

NCT04371224 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Irinotecan Liposomal Injection [Onivyde]
DRUG: Capecitabine
DRUG: 5-fluorouracil
DRUG: Leucovorin

Sponsor

Seoul National University Hospital